IDYA IDEAYA Biosciences (IDYA) Insider Trading, Ownership & Congress Trades
Pharma & Biotech · Pharmaceutical preparations · CIK 0001676725
Form 144 · 1
Insider buyers, 180 days
0
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
158
13F, latest reported quarter
Conversions, 180 days
2
Codes C/M, not in net · $236.3K priced
What the filings say about IDYA
Insiders, 180 days
-$1.4M net sold
2 sellers · 67% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$8.8M
1 notice
IDEAYA Biosciences insider trades (Form 4)
Form 4 buys and sells (codes P and S). Grants, option exercises
and conversions excluded.
Over the last 180 days, IDEAYA Biosciences, Inc. insiders sold a net $1.4M of stock across 60 Form 4 purchases and sales, with no insider buying. Source: SEC Form 4 filings, as of 2026-10-28.
Insider
Filed
Shares
Value
Since filing
Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on May 16, 2024.
- The trade is 3.7% of the 691,495 shares held after it.
- No other insider sold within 30 days.
- 158 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Hata Yujiro S sold about $954.8K of IDYA under a 10b5-1 plan on Oct 6, 2026, the largest insider sale at the company since 2024; 158 funds added in the latest 13F quarter.Context
- 14 earlier Form 4 trades (code P or S) here by this insider (14 sales), the last on May 16, 2024.
- The trade is 0.1% of the 690,695 shares held after it.
- No other insider sold within 30 days.
- 158 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: President and CEO Hata Yujiro S sold about $30.6K of IDYA under a 10b5-1 plan on Oct 6, 2026; 158 funds added in the latest 13F quarter.Context
- 6 earlier Form 4 trades (code P or S) here by this insider (6 sales), the last on Feb 9, 2024.
- The trade is 36.1% of the 26,466 shares held after it.
- No other insider sold within 30 days.
- 158 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Accounting Officer Ruiz Briseno Andres sold about $382.1K of IDYA on Jul 7, 2026, the largest insider sale at the company since 2024; 158 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 92.1% of the 54,281 shares held after it.
- No other insider bought within 30 days.
- 158 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Director Stein Jeffrey bought about $1.6M of IDYA on Mar 2, 2026, the largest insider purchase at the company on our record; 158 funds added in the latest 13F quarter.Context
- First Form 4 purchase or sale (code P or S) here by this insider on our record.
- The trade is 3249.0% of the 851 shares held after it.
- 1 other insider sold within 30 days.
- 158 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer WHITE MICHAEL ANTHONY sold about $1.0M of IDYA on May 29, 2024; 1 other insider sold within 30 days and 158 funds added in the latest 13F quarter.60 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
Seven facts, ranked against the sector ·
Rank is not a forecast
Insiders
net -$1.4M over 180 days
-$985.4K over 90 days
below 65% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
158 funds bought in last quarter
more than 84% of Pharma & Biotech
Revenue
+3024.4% year over year
more than 98% of Pharma & Biotech
Margin
-52.0% net margin
below 51% of Pharma & Biotech
Buybacks
no share repurchases reported
Short interest
10.1% of the float short (float per yahoo 2026-10-26) · 8.4 days to cover · settled 2026-09-30
more than 69% of Pharma & Biotech
What changed in the last 30 days
Oct 8President and CEO Hata Yujiro S sold $985.4K under a 10b5-1 plan (Oct 6)
Why it matters
A 10b5-1 plan schedules trades months ahead, so this says little about what the insider thinks today.
Oct 6CEO YUJIRO HATA filed to sell $8.8M by Oct 6 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Watch IDYA
A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.
The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
+15.7%12M
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart.
When a name files heavily, the largest trades are drawn first.
Who owns IDYA: institutional holders (13F)
13F holdings, latest reported quarter
14,109,431 sh
$525.9M
8,893,260 sh
$331.5M
8,579,881 sh
$319.7M
5,344,701 sh
$199.2M
5,010,030 sh
$186.7M
Congress trades in IDYA
No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.
Activist and 5% holders (13D/13G)
No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.
IDYA planned insider sales (Form 144)
Notice of intent to sell, filed before any sale
YUJIRO HATA
Filed 2026-10-06
$8.8M
Andres Ruiz Briseno
Filed 2026-07-07
$382.1K
IDYA mutual fund holders (N-PORT)
Funds ranked by the share of their own portfolio in this stock (N-PORT).
iShares Genomics Immunology and Healthcare ETF
$6.4M position · as of 2026-07-31
3.4%
Tema Oncology ETF
$4.0M position · as of 2026-05-31
2.3%
NYLIM Fiera SMID Growth Fund
$3.7M position · as of 2026-07-31
1.8%
ALPS Medical Breakthroughs ETF
$2.7M position · as of 2026-05-31
1.6%
Jacob Discovery Fund
$245.6K position · as of 2026-05-31
1.5%
Virtus Biotech Clinical Trials Etf
$380.7K position · as of 2026-07-31
0.8%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M ·
% is the share of the fund's own portfolio
Clinical pipeline
11 registered trials, 11 still running (ClinicalTrials.gov).
A status change is dated here weeks before the press release.
5
Phase 1
5 active
1
Phase 2
1 active
2
Phase 3
2 active
3
Multi-phase
3 active
Matched by sponsor name. Trials run under a subsidiary's
own name are not included.
Executive pay vs shareholder return
CEO pay, headline and as actually paid, against the company's
return and its chosen peers' (DEF 14A).
FY
CEO total
Actually paid
Other execs, avg
TSR
Peer TSR
2025
$9.5M
$15.7M
$2.7M
+147%
+25%
2024
$16.9M
$5.8M
$4.5M
+84%
-7%
2023
$6.0M
$15.7M
$2.0M
+154%
-6%
2022
$3.3M
$1.8M
$2.0M
+30%
-10%
2021
$3.8M
$7.3M
$2.5M
+69%
+0%
Tagged by the company under SEC Item 402(v). Returns are
cumulative from the start of the disclosure period. Green where the company beat its own peer group.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $1.4M sold by insiders over 180 days, 158 funds added last quarter, $8.8M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
IDYA financials
Revenue growth
+3024.4%
XBRL, annual
Net margin
-52.0%
Ratios from the company's XBRL filings, latest filings
Revenue, TTM
$234.1M
four quarters, 2025-07-01 to 2026-06-30
Revenue, TTM IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | $7.0M |
| FY Dec 2023 | $23.4M |
| FY Dec 2022 | $50.9M |
| FY Dec 2021 | $27.9M |
| Jun 2026 | $8.9M |
| Mar 2026 | $6.6M |
| Dec 2025 | $10.9M |
| Sep 2025 | $207.8M |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | $7.0M |
| Sep 2024 | $0 |
At each fiscal year end
Single quarter
Net margin, TTM
-74.8%
net income over revenue, 2025-07-01 to 2026-06-30
Net margin, TTM IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | -3,921% |
| FY Dec 2023 | -483.1% |
| FY Dec 2022 | -115.2% |
| FY Dec 2021 | -178.1% |
| Jun 2026 | -1,270% |
| Mar 2026 | -1,502% |
| Dec 2025 | -765.7% |
| Sep 2025 | +57.4% |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | -1,862% |
| Sep 2024 | n/a |
At each fiscal year end
Single quarter
Free cash flow, TTM
-$113.9M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Free cash flow, TTM IDYA
| FY Dec 2025 | -$73.5M |
| FY Dec 2024 | -$251.4M |
| FY Dec 2023 | -$117.6M |
| FY Dec 2022 | -$90.6M |
| FY Dec 2021 | -$58.4M |
| Jun 2026 | -$89.1M |
| Mar 2026 | -$76.1M |
| Dec 2025 | -$90.8M |
| Sep 2025 | $142.2M |
| Jun 2025 | -$63.1M |
| Mar 2025 | -$61.7M |
| Dec 2024 | -$122.8M |
| Sep 2024 | -$49.7M |
At each fiscal year end
Single quarter
Debt to equity
n/a
no debt line filed
Debt to equity IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Cash flow to debt
n/a
no debt line filed
Cash flow to debt IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on equity
-16.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on equity IDYA
| FY Dec 2025 | -10.9% |
| FY Dec 2024 | -32.7% |
| FY Dec 2023 | -23.3% |
| FY Dec 2022 | -18.0% |
| FY Dec 2021 | -19.9% |
| Jun 2026 | -16.2% |
| Mar 2026 | -14.3% |
| Dec 2025 | -10.9% |
| Sep 2025 | -14.1% |
| Jun 2025 | -35.1% |
| Mar 2025 | -31.3% |
| Dec 2024 | -32.7% |
| Sep 2024 | -21.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on assets
-14.9%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets IDYA
| FY Dec 2025 | -10.2% |
| FY Dec 2024 | -31.0% |
| FY Dec 2023 | -21.8% |
| FY Dec 2022 | -15.2% |
| FY Dec 2021 | -14.6% |
| Jun 2026 | -14.9% |
| Mar 2026 | -13.1% |
| Dec 2025 | -10.2% |
| Sep 2025 | -13.3% |
| Jun 2025 | -32.9% |
| Mar 2025 | -29.8% |
| Dec 2024 | -31.0% |
| Sep 2024 | -20.1% |
At each fiscal year end
Trailing four quarters at each quarter end
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on invested capital IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Return on capital employed
-19.6%
operating income (EBIT proxy) over average of 2025-06-30 and 2026-06-30 minus current liabilities
Return on capital employed IDYA
| FY Dec 2025 | -15.0% |
| FY Dec 2024 | -38.5% |
| FY Dec 2023 | -27.5% |
| FY Dec 2022 | -18.1% |
| FY Dec 2021 | -16.9% |
| Jun 2026 | -19.6% |
| Mar 2026 | -18.2% |
| Dec 2025 | -15.0% |
| Sep 2025 | -18.0% |
| Jun 2025 | -40.0% |
| Mar 2025 | -36.3% |
| Dec 2024 | -38.5% |
| Sep 2024 | -26.3% |
At each fiscal year end
Trailing four quarters at each quarter end
P/E, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
P/E, trailing IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Enterprise value
n/a
no debt line filed
Enterprise value IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
FCF yield
-3.6%
TTM free cash flow over market value at close 2026-10-26
FCF yield IDYA
| FY Dec 2025 | -2.4% |
| FY Dec 2024 | -11.3% |
| FY Dec 2023 | -5.1% |
| FY Dec 2022 | -10.4% |
| FY Dec 2021 | -6.4% |
| Jun 2026 | -3.5% |
| Mar 2026 | -3.0% |
| Dec 2025 | -2.4% |
| Sep 2025 | -4.4% |
| Jun 2025 | -16.1% |
| Mar 2025 | -18.7% |
| Dec 2024 | -11.3% |
| Sep 2024 | -5.7% |
At each fiscal year end
Trailing four quarters at each quarter end
PEG, trailing
n/a
trailing loss, a multiple of a loss is not meaningful
PEG, trailing IDYA
| FY Dec 2025 | n/a |
| FY Dec 2024 | n/a |
| FY Dec 2023 | n/a |
| FY Dec 2022 | n/a |
| FY Dec 2021 | n/a |
| Jun 2026 | n/a |
| Mar 2026 | n/a |
| Dec 2025 | n/a |
| Sep 2025 | n/a |
| Jun 2025 | n/a |
| Mar 2025 | n/a |
| Dec 2024 | n/a |
| Sep 2024 | n/a |
At each fiscal year end
Trailing four quarters at each quarter end
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
| 2025-12 | 2024-12 | 2023-12 | 2022-12 | |
|---|---|---|---|---|
| Revenue | $218.7M | $7.0M | $23.4M | $50.9M |
| Operating income | -$159.3M | -$327.0M | -$134.4M | -$62.5M |
| Net income | -$113.7M | -$274.5M | -$113.0M | -$58.7M |
| EPS (diluted) | -1.28 | -3.36 | -1.96 | -1.42 |
| Operating cash flow | -$71.1M | -$247.6M | -$115.2M | -$87.2M |
| Cash | $112.8M | $84.4M | $157.0M | $68.6M |
SEC XBRL, fiscal years, as known on 2026-10-28
IDYA Stock Sonar score 5/7 axes
Find similar shapesCompareIDYA ranks highest on growth (98th percentile) and institutional and government (84th), and lowest on insider conviction (22nd), among Pharma & Biotech peers.
5 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored
IDYA filings, in plain words
Are IDEAYA Biosciences insiders buying or selling IDYA?
In the 180 days to 2026-10-28, IDEAYA Biosciences insiders were net sellers, a net $1.4M across purchases and sales reported on Form 4, by 2 sellers.
Are there planned insider sales of IDYA?
Yes. 1 Form 144 notice of planned insider sales was filed in the 90 days to 2026-10-28, covering $8.8M of stock; the latest, by YUJIRO HATA, was filed 2026-10-06.
Read the full summary
In the 180 days to 2026-10-28, IDEAYA Biosciences insiders were net sellers of IDYA, a net $1.4M across purchases and sales reported on Form 4 by 2 sellers. 67% of the 3 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 1 Form 144 notice of intent to sell in the 90 days to 2026-10-28, covering $8.8M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.
Explore insider trading and ownership data
Every company we track, ranked by each kind of filing
